이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Nanjing Vishee Medical Technology 관리

관리 기준 확인 2/4

Nanjing Vishee Medical Technology's CEO는 Zhiyu Wang, Nov2021 에 임명되었습니다 의 임기는 2.58 년입니다. 는 CN¥ 1.05B 가치에 해당하는 회사 주식의 39.78% 직접 소유합니다. 1.05B. 경영진과 이사회의 평균 재임 기간은 각각 2.6 년과 2.6 년입니다.

주요 정보

Zhiyu Wang

최고 경영자

CN¥1.7m

총 보상

CEO 급여 비율	n/a
CEO 임기	2.6yrs
CEO 소유권	39.8%
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	2.6yrs

최근 관리 업데이트

Recent updates

Investors Don't See Light At End Of Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) Tunnel

Jun 06

Solid Earnings May Not Tell The Whole Story For Nanjing Vishee Medical Technology (SHSE:688580)

May 02

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) Shares Fly 30% But Investors Aren't Buying For Growth

Mar 06

Nanjing Vishee Medical Technology Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Feb 29

CEO

Zhiyu Wang (57 yo)

2.6yrs

테뉴어

CN¥1,728,300

보상

Mr. Zhiyu Wang serves as General Manager & Chairman of the Board and General Manager at Nanjing Vishee Medical Technology Co., Ltd.

리더십 팀

이름	위치	테뉴어	보상	소유권
Zhiyu Wang	GM & Chairman of the Board	2.6yrs	CN¥1.73m	39.78% CN¥ 1.0b
Chen Lili	CFO & Director	2.6yrs	CN¥711.30k	0.014% CN¥ 351.1k
Zhang Hui	Chief Operating Officer	2.6yrs	CN¥651.90k	0.017% CN¥ 421.5k
Jinguo Xu	Deputy GM & Director	2.6yrs	CN¥48.10k	데이터 없음
Wenlong Liu	Director of Product Department	7yrs	CN¥548.80k	데이터 없음
Zhong Yiqun	Deputy GM & Secretary	2.6yrs	CN¥693.70k	0.014% CN¥ 351.1k
Kai Qiu	Senior R&D Director and Core Technician	2.6yrs	CN¥670.00k	0.022% CN¥ 561.9k
Fei Gao	R&D Manager and Core Technician	9yrs	CN¥567.00k	데이터 없음

2.6yrs

평균 재임 기간

43.5yo

평균 연령

경험이 풍부한 관리: 688580 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zhiyu Wang	GM & Chairman of the Board	no data	CN¥1.73m	39.78% CN¥ 1.0b
Chen Lili	CFO & Director	2.6yrs	CN¥711.30k	0.014% CN¥ 351.1k
Jinguo Xu	Deputy GM & Director	no data	CN¥48.10k	데이터 없음
Ping Hu	Chairman of the Supervisory Board	2.6yrs	데이터 없음	16.57% CN¥ 420.6m
Weihua Cai	Independent Director	2.6yrs	CN¥60.00k	데이터 없음
Xiao Junfang	Independent Director	2.6yrs	CN¥60.00k	데이터 없음
Gu Ying	Member of Supervisory Board	2.6yrs	데이터 없음	데이터 없음
Xiaoming Li	Director	2.6yrs	데이터 없음	0.26% CN¥ 6.5m
Jialu Wu	Independent Director	1.1yrs	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

45.5yo

평균 연령

경험이 풍부한 이사회: 688580 의 이사회는 경험(평균 재직 기간 2.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Nanjing Vishee Medical Technology 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Investors Don't See Light At End Of Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) Tunnel

Now 22% undervalued after recent price drop

Solid Earnings May Not Tell The Whole Story For Nanjing Vishee Medical Technology (SHSE:688580)

Nanjing Vishee Medical Technology Co., Ltd, Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.44 in 1Q 2023)

Nanjing Vishee Medical Technology Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) Shares Fly 30% But Investors Aren't Buying For Growth

Nanjing Vishee Medical Technology Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) announces an Equity Buyback for CNY 40 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.46 (vs CN¥0.35 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.31 in 2Q 2022)

Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 24%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%, revenue upgraded

Investor sentiment improves as stock rises 15%

Less than half of directors are independent

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) agreed to acquire a 70% stake in Hefei Hans Curestar Laser Device Co., Ltd. from Wang Bizhan, Huang Heng, Yang Aichun and Xu Qingfen for CNY 58.8 million.

Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.56 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.55 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) announces an Equity Buyback for CNY 40 million worth of its shares.

Consensus revenue estimates fall by 13%

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.51 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥2.46 (vs CN¥1.95 in FY 2019)

New 90-day high: CN¥121

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥89.35

New 90-day low: CN¥98.30

New 90-day low: CN¥114

Market pulls back on stock over the past week

New 90-day low: CN¥156

Nanjing Vishee Medical Technology Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령